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Background The global impact of the 2009 influenza A(H1N1)
pandemic (H1N1pdm) is not well understood.
Objectives We estimate overall and age-specific prevalence of
cross-reactive antibodies to H1N1pdm virus and rates of
H1N1pdm infection during the first year of the pandemic using
data from published and unpublished H1N1pdm
seroepidemiological studies.
Methods Primary aggregate H1N1pdm serologic data from each
study were stratified in standardized age groups and evaluated
based on when sera were collected in relation to national or
subnational peak H1N1pdm activity. Seropositivity was assessed
using well-described and standardized hemagglutination inhibition
(HI titers  32 or  40) and microneutralization (MN  40)
laboratory assays. The prevalence of cross-reactive antibodies to
the H1N1pdm virus was estimated for studies using sera collected
prior to the start of the pandemic (between 2004 and April 2009);
H1N1pdm cumulative incidence was estimated for studies in
which collected both pre- and post-pandemic sera; and
H1N1pdm seropositivity was calculated from studies with post-
pandemic sera only (collected between December 2009–June
2010).
Results Data from 27 published/unpublished studies from 19
countries/administrative regions – Australia, Canada, China,
Finland, France, Germany, Hong Kong SAR, India, Iran, Italy,
Japan, Netherlands, New Zealand, Norway, Reunion Island,
Singapore, United Kingdom, United States, and Vietnam – were
eligible for inclusion. The overall age-standardized pre-pandemic
prevalence of cross-reactive antibodies was 5% (95%CI 3–7%)
and varied significantly by age with the highest rates among
persons  65 years old (14% 95%CI 8–24%). Overall age-
standardized H1N1pdm cumulative incidence was 24% (95%CI
20–27%) and varied significantly by age with the highest in
children 5–19 (47% 95%CI 39–55%) and 0–4 years old (36%
95%CI 30–43%).
Conclusions Our results offer unique insight into the global impact
of the H1N1 pandemic and highlight the need for standardization of
seroepidemiological studies and for their inclusion in pre-pandemic
preparedness plans. Our results taken together with recent global
pandemic respiratory-associated mortality estimates suggest that the
case fatality ratio of the pandemic virus was approximately 002%.
Keywords A(H1N1)pdm09, cross-reactive antibodies, cumulative
incidence, H1N1pdm, seroprevalence.
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Introduction
Soon after detection of the novel pandemic influenza A
(H1N1)2009 virus (H1N1pdm) in Mexico and the United
States in April 2009,3 countries across the globe began
reporting laboratory confirmed H1N1pdm cases to the
World Health Organization (WHO).4 However, as case
numbers increased, laboratories were overwhelmed with
demand for testing. WHO responded with new guidance in
June 2009 asking that countries report the first cases detected
in a country, that testing focus on fatal and severe cases, and
for countries to only report fatal cases to WHO.5 As a result,
by the time, the pandemic was declared over in August 2010,6
numbers of cases and deaths (<1 million and >18 449,7
respectively) reported to WHO represented only a small
fraction of the true burden of infection and mortality due to
H1N1pdm.
Even in well-resourced countries, the very large numbers
of H1N1pdm cases, the non-specificity of clinical case
definitions for influenza, and finite testing capacity means
that incidence cannot be estimated from case-based sur-
veillance. This information is critical to understanding the
overall morbidity, mortality, and population-level severity
of the H1N1pdm virus, as it serves as the denominator for
the estimation of severity measures. Along with population-
level surveillance to capture numerators (i.e., H1N1pdm,
hospitalizations and deaths), representative serological stud-
ies are designed to collect denominator data (i.e., infections)
that can be used to estimate severity parameters such as the
CFR (i.e., the total number of H1N1pdm deaths divided by
the total number of H1N1pdm infections) and hospitaliza-
tion ratios (number of H1N1pdm hospitalizations divided
by H1N1pdm infections). Thus, analysis of serological data
can provide accurate measures of incidence, reduce the
uncertainty around severity assessment, and help inform
the appropriate intensity and targeting of mitigation
policies.8–10
As well as estimating the proportion of the population
infected by a particular virus, data from seroepidemiological
studies can provide insights into age-specific and regional
trends in incidence and cross-protective immunity, which are
important to characterize the infectivity of a new virus,
identify key target groups for interventions and for develop-
ing mitigation measures.8–11 Insight into cross-protective (or
partial) immunity acquired from exposure to other influenza
strains or vaccination is of particular scientific interest.
Knowing what proportion of the population had antibodies
before the first wave and how this immunity affected
subsequent circulation of the virus provides valuable infor-
mation for understanding the transmission dynamics of
influenza pandemics more generally.
A number of early seroepidemiological studies using
residual sera collected prior to the start of the H1N1pdm
pandemic were conducted within months of identification of
the H1N1pdm virus to assess the level of pre-existing
immunity in the population by age, quickly followed by
investigations from a number of countries to estimate the
proportion of the population infected with the H1N1pdm
virus.12 Together with early investigations elucidating age-
specific clinical attack rates13,14 and transmission character-
istics15 of the new virus, these studies provided critical input
into and reduced uncertainty around national and global
policy decisions. Numerous seroepidemiological studies have
subsequently been published, but the comparison and direct
interpretation of the results of serological studies is difficult
due to the varied epidemiological methods used to collect
sera, the heterogeneity in the populations under study,
variation in laboratory assays used, and criteria for
seropositivity.12,16
The objective of this study is to bring together all available
original serological data in a standardized format from
H1N1pdm seroepidemiological studies to estimate the pro-
portion of the population with cross-reactivity antibodies to
H1N1pdm prior to the start of the pandemic and to estimate
age-specific cumulative incidence of H1N1pdm infection
during the first year of the pandemic. This study builds upon
the findings of Kelly et al.17 by including a number of
additional H1N1pdm serologic studies conducted from a
number of additional countries since this publication.
Combined with what is known about morbidity and
mortality of the pandemic virus around the world, these
estimates provide a better sense of the overall global impact
of the H1N1 pandemic.
This study represents the combined work and collabora-
tion of influenza researchers from more than 27 different
research groups around the world and is the first of its kind
to use original data to produce a summary estimate from a
global perspective of the proportion of the population that
was infected during the first year of the influenza pandemic
of 2009. Our analysis includes original serologic data from
several low- and middle-income countries including China,
India, Iran, Vietnam, and Reunion Island and high-income
countries, including Australia, Canada, Finland, France,
Germany, Hong Kong SAR, Italy, Japan, Netherlands, New
Zealand, Norway, Singapore, United Kingdom, and the
United States.
This work provides critical insight into the underappre-
ciated impact and severity of the pandemic, and our results
are of great value in planning and preparing for the next
pandemic. Age-specific cumulative incidence rates are critical
parameters used by public health decision makers and
mathematical modelers in planning for and responding to a
pandemic and provide accurate denominator estimates to
calculate a key parameter – the case fatality ratio. Together
with recent1 and forthcoming2 estimates of H1N1pdm
mortality – the numerator of the case fatality ratio (CFR) –
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and our summary cumulative incidence results, we suggest
that the CFR of the pandemic virus was approximately 002%
providing insight into the severity of the 2009 influenza
pandemic globally.
Methods
An extensive literature search for H1N1pdm serological
studies was conducted using a keyword-based computerized
search of the National Library of Medicine through
PubMed. The search was limited to all H1N1pdm se-
roepidemiological studies published by 1 January 2012.
Articles with the MeSH keywords: human influenza,
pandemic, sero-incidence, and seroprevalence, in their titles
or abstract were reviewed for eligibility for inclusion. The
references cited in screened articles were further inspected
by SH and MDVK to identify additional relevant studies
(any discrepancies were discussed with AWM; Figure 1a).
In addition to published studies, the WHO Global Influ-
enza Programme contacted researchers known to be
conducting serological studies from a comprehensive list
of planned and ongoing H1N1pdm serological studies
compiled and maintained by WHO. Additionally, a further
effort was made to identify unpublished studies by
contacting experts and known influenza researchers by
searching influenza conference proceedings and country
surveillance agency reports. Researchers of unpublished
studies were asked to share their study methodology
(further details below) and preliminary results to allow
assessment for inclusion. As with published studies,
unpublished data were also used only if data were available
by 1 January 2012.
Inclusion/exclusion criteria
Inclusion criteria
Published and unpublished studies that measured overall
and age-stratified antibody titers against H1N1pdm 2009
influenza virus by well-described and standardized hemag-
glutination inhibition (HI) and microneutralization (MN)
laboratory assays were included. Briefly, seropositivity was
assessed as assay HI titers  32 or MN assay  40.
Additionally, serological studies that measured cross-reac-
tive antibodies to H1N1pdm influenza virus in sera
collected prior to the start of the 2009 pandemic were
included to quantify age-stratified pre-existing cross-reac-
tive antibody levels in populations. To be included, authors
of individual studies were required to provide results in
harmonized age groups (0–4; 5–19; 20–44; 45–64 and
 65 years old) and additional details about their study
population (e.g., specific start and end dates for sera
collection, sample size in each age group, assay and criteria
for seropositivity, description(s) of study populations from
which sera was used, specific location(s) of residence of
subjects providing sera, and use of seasonal and pandemic
vaccination among included sera, if possible). When use of
H1N1pdm vaccine was available in individual studies, we
asked authors to provide results among unvaccinated
persons only.
Exclusion criteria
Clinical vaccine trials were excluded, as were serological
studies of avian and seasonal (H1N1 or H3N2) influenzas.
Additionally, studies of populations in closed settings (i.e.,
military facilities, schools) or among specific populations
only (e.g., HIV-infected individuals or pregnant women)
were excluded. Finally, studies that included only H1N1pdm
vaccinated individuals were excluded.
Data abstraction, synthesis and statistical methods
used for metanalysis
Data from included studies were categorized based on when
sera were collected in relation to national, or subnational
where available, 2009–2010 virologic H1N1pdm activity18
(Figure 1b; categories: pre-pandemic sera, pre- and post-
pandemic sera and post-pandemic sera only). Studies that
only collected sera during the peak of H1N1pdm virologic
activity were excluded from the analyses (Figure 1b, shaded
area). For all three different sets of analyses: overall and age-
specific prevalence of cross-reactive antibodies to the
H1N1pdm virus using pre-pandemic sera, overall and
age-specific cumulative incidence using studies with both
pre- and post-pandemic sera and overall and age-specific
seroprevalence using studies with post-pandemic sera only,
we used random effects (at the study level) logistic regres-
sions to obtain pooled overall and age-specific estimates as
well as to take into account the heterogeneity of results
between studies.
A database was created (by SH and MDVK) to collate
extracted information from each study including: country of
study, author and year of publication, laboratory assay(s)
used, cut-off value used for determining seropositivity,
description of study population from whom sera was
collected, period(s) when sera were collected, sample size,
proportion seropositive with 95% confidence intervals,
timing of the national peak pandemic activity for the
relevant country according to data reported to FluNet,18
timing of H1N1pdm vaccination campaign for the country,
use of seasonal vaccine among study population (if avail-
able), and difference between timing of sera collection and
H1N1pdm peak virologic activity (in weeks). Because
different studies used different age categories for reporting
seropositivity results in their individual publications,
we requested all researchers to share their seropositivity
results for five age categories (0–4; 5–19; 20–44; 45–64,
and  65 years old) to ensure comparability. These age
Van Kerkhove et al.
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categories were chosen based on differences in the epidemi-
ology and reported clinical severity of the disease in these age
groups.19 Overall pooled estimates were age-adjusted using
age-specific population estimates from the UN.20 To evaluate
seroprevalence levels over time, we explored age-specific
post-pandemic seroprevalence versus the difference in timing
of sera collection and the national peak of H1N1pdm virus
activity.
Pre-pandemic sera to estimate prevalence of cross-
reactive antibodies to the H1N1pdm virus
All sera collected prior to April 1 2009, regardless of study
design, were classified as pre-pandemic sera for which
baseline overall and age-specific cross-reactive antibodies to
the H1N1pdm virus were estimated (Figure 1b). We mod-
eled overall and age-specific pre-pandemic prevalence of
cross-reactive antibodies from studies with sera collected
74 articles listed in PubMed
11 unpublished studies 
identified through other 
sources
32 published/8 
unpublished articles 
reviewed in depth
27 published/unpublished 
papers included
42 articles excluded
•Review article
•Focus on avian flu subtype
•Focus on seasonal flu subtype
•Focus on outbreak investigation of 
specialized populations
•Focus on special populations
3 unpublished studies excluded
•Age-specific results not available
5 published studied excluded
•Age specific results not available
•Excluded based on laboratory 
methods
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Figure 1. (a) Review process of published and unpublished H1N1pdm serologic literature search. (b) Example of the characterization of timing of sera
collection in relation to national H1N1pdm virus activity. N.B. Characterization of sera timing was conducted using the national, or subnational when
available, epidemic curve separately for each country that provided serological data, Time period A indicates the time period prior to the reporting of the
first H1N1pdm cases in North America and start of the 2009 influenza pandemic. Time period B indicates the time period after the H1N1pdm virus was
identified in North America, but before wide-spread circulation of the virus occurred in each country. This assessment was made for each individual
country or subnational geographic area if subnational virologic data were available. Time period C indicated the time after the national or subnational
peak in H1N1pdm virologic activity was over, but not completely back to baseline levels. Time period D indicates the national or subnational time when
H1N1pdm virus circulation was clearly over. Shaded area indicates example of peak H1N1pdm virologic activity. Studies that collected sera during peak
activity were excluded from the analyses.
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prior to April 2009 (Figure 1b, area indicated as time period
A) and studies that included sera collected prior to
widespread community transmission (see Figure 1b, time
period B). We then explored, in addition to other possible
causes of heterogeneity (described below), whether study
timing explained any of differences (i.e., whether the pre-
pandemic prevalence of cross-reactive antibodies differed
between studies conducted at time period A versus B). Only
studies that analyzed seropositivity using HI were included in
pre-pandemic analyses. Details of the included studies are
provided in Table S1.
Pre- and post- pandemic sera to estimate
cumulative incidence
For studies that had both pre- (Figure 1b time period A or B)
and post- pandemic sera (Figure 1b, time period C or D)
according to the national or subnational period of H1N1pdm
virus circulation, overall and age-specific cumulative inci-
dence were calculated for each study by taking the difference
in seroprevalence. In included studies, sera were collected
twice from the same subject (paired sera from longitudinal
studies) or twice in the same population but from different
individuals (unpaired sera from cross-sectional studies)
before the start of the pandemic and after the pandemic
was over. Studies that analyzed seropositivity by HI and MN
were included in incidence calculations. Details of the
included studies are provided in Table S2.
Post-pandemic sera to estimate H1N1pdm
seroprevalence
Finally, we modeled and provided pooled overall and
age-specific H1N1pdm seroprevalence from post-pandemic
sera, that is, sera collected during time periods, which
coincided with a decline in national or subnational
H1N1pdm transmission (Figure 1b, time period C) or when
transmission ceased (Figure 1b, time period D). Only studies
that analyzed seropositivity using HI were included in post-
pandemic analyses. Details of the included studies are
provided in Table S3.
Meta-regression
We explored differences in the outcomes listed above for all
three sets of analyses, by adjusting for one covariate at a time
in the random effects logistic regressions. Such models allow
for within and between study variation to be included in the
estimated coefficients. The covariates considered in the
relevant univariable random effects logistic regressions were:
study timing for the pre- and post- pandemic single sera
analyses (i.e., we examined whether there were differences: (i)
for the pre-pandemic studies, between studies conducted at
time period A and B in Figure 1b, and (ii) for the
post-pandemic single sera studies, between studies conducted
at time period C and D in Figure 1b, respectively); assay
(HI  1:32; HI  1:40; MN  1:40; for estimates of
H1N1pdm cumulative incidence, only); subject type; country
and geographic region of sera collection; if H1N1pdm
vaccination was used in the included countries; and
population density at the national level.21
Results
Included studies
Seventy-four articles were identified for title and abstract
review, and 32 full-text articles were retrieved and reviewed
(Figure 1a). Twenty-seven studies, including eight
unpublished studies (at the time of data collection), were
included in the meta-analysis (Table 1). Of those, 19 studies
from 15 countries included pre-pandemic sera in which
overall and age-specific prevalence of cross-reactive antibod-
ies were estimated22–40 (details of included studies are shown
in Table S1); 12 studies from 11 countries contained
both pre-and post-pandemic in which overall and age-
specific H1N1pdm cumulative incidence were esti-
mated22,23,29–34,38,39,41–43 (Table S2); and 10 studies from
nine countries contained post-pandemic sera in which
overall and age-specific H1N1pdm seroprevalence were
estimated35–37,44–49 (Sridhar S, personal communication;
Table S3).
In total, our analysis was based on approximately 90 000
serological samples from 19 countries and/or administrative
regions, including Australia, Canada, China, Finland, France,
Germany, Hong Kong SAR, India, Iran, Italy, Japan,
Netherlands, New Zealand, Norway, Reunion Island, Singa-
pore, the United Kingdom (UK), the United States (US), and
Vietnam (Figure 2). Pre-pandemic seroprevalence data were
available from Chinese Taipei, but excluded from the pooled
results because results were only available by MN (Sridhar S,
et al. personal communication, Chen M. personal commu-
nication).9,22–28,30–32,34–39,41,42,44,46–51 Pre- and post-pan-
demic sera from Greece were excluded from the cumulative
incidence results because seropositivity was analyzed by
enzyme-linked immunosorbent assay (ELISA), a novel
method developed by the researchers and not fully
validated.52
Pre-pandemic prevalence of cross-reactive
antibodies
The pre-pandemic prevalence of cross-reactive antibodies
were estimated from pooling serological data from 15
countries from 19 studies (n sera = 15 476). The overall
age-adjusted pre-pandemic prevalence of elevated cross-
reactive H1N1pdm antibodies was 5% (95%CI 3–7%;
Table 1; Figure 3A). Prevalence increased with age
(Figure 4A; 0–4 years old 1% [03–4%], 5–19 years old 4%
[1–9%], 20–44 years old 5% [3–8%], 45–64 years old 5% [2
–9%]) and was highest in subjects 65 years and older (14%
Van Kerkhove et al.
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[8–24%]). Overall, there were significant differences in
prevalence by region, with individuals from Asia less likely
and subjects from one site in Africa (Reunion Island) more
likely to have cross-reactive antibodies to H1N1pdm when
compared with Europe (OR = 0098 95%CI 001–09);
OR = 92 95%CI 19–438), respectively). Subjects from
one site in Africa also had higher seroprevalence among
5–19 (OR = 142 95%CI 12–1749), 20–44 (OR = 69 95%
CI 33–144), 45–64 (OR = 214 95%CI 42–1100) and  65
(OR = 170 95%CI 23–1272)-year-old age groups when
compared with individuals from Europe in the same age
groups. Subjects 20–44 years old from Asia had lower
seroprevalence when compared with Europe (OR = 020
95%CI 01–04). Subjects from one study of rural households
(Vietnam) had lower overall pre-pandemic seroprevalence
than outpatients (OR = 006 95%CI 0004–08). There were
Table 1. Characteristics of included studies for each of the age-specific and age-standardized pooled estimates
Estimate
Age-specific H1N1pdm cross-reactive
antibodies
Age-specific H1N1pdm cumulative
incidence
Age-specific H1N1pdm
seroprevalence
Description of sera
included in
estimate
Studies, which included pre-pandemic sera Studies, which included both pre- and
post-pandemic sera
Studies, which included post-
pandemic sera (only)
Source of sera (n
countries)
Australia, Canada, China, Finland, France,
Germany, India, Italy, Japan, New Zealand,
Norway, Reunion Island, Singapore, UK, USA
(15)
Australia, Canada, France, Germany,
Hong Kong SAR, Japan, New Zealand,
Norway, UK, USA, Vietnam (11)
Canada, China, France,
Germany, Iran, Netherlands,
Reunion Island, Singapore, UK,
USA (9)
Number of studies
included in
estimates
19 12 10
Number of sera
samples included
in analyses
15 476 Pre-pandemic sera = 9910
Post-pandemic sera = 14 228
52 479
Assays used and
criteria for
seropositivity
HI  1:32* or HI  1:40 HI  1:32; HI  1:40; MN  1:40 HI  1:40**
Overall age-
standardized
pooled estimate
(95% CI)
5% (3–7%) 24% (20–27%) 32% (26–39%)
See Tables S1–S3 in the Supporting information for details of individual studies.
HI, hemagglutination inhibition; MN, microneutralization assay.
*Hardelid et al.41 and Iwatsuki-Horimoto et al. (2011) only; all other studies used HI  1:40 as criteria for seropositivity.
**All studies in H1N1pdm seroprevalence estimates used HI  1:40 as criteria for seropositivity.
Figure 2. Geographic distribution of included study populations.
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no significant differences in pre-pandemic seroprevalence
and any other covariate under investigation.
Cumulative incidence of pandemic influenza
infection
Data used to estimate age-specific cumulative incidence were
available from 11 countries and 12 studies (Table 1; Table
S2). The overall age-adjusted cumulative incidence of
H1N1pdm infection based on the difference between pre-
and post-pandemic seroprevalence was 24% (95%CI 20–
27%, Figure 3B) and varied significantly by age (Figure 4B).
The highest age-specific incidence was found among children
5–19 years old (46% [36–56%]), followed by 0–4 years old
(37% [30–44%]) and decreased by age from 20 years old and
older (20–44 years old 20% [13–26%], 45–64 years old 14%
[9–20%]). The lowest incidence was found in those
 65 years old (11% [5–18%]).
There were significant associations found between inci-
dence and region and subject type in the overall estimate,
indicating that overall cumulative incidence was 28% lower
(95%CI 77–484) in Asia when compared with Europe
and 23% lower (95%CI 31–427) in subjects from rural
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households (Vietnam) compared with countries sampling
from outpatients. Samples from subjects 5–19 years old from
Asia and Oceana had lower cumulative incidence that samples
from Europe in the same age group (29% [95%CI 158–419]
lower, 21% [95%CI 31–393] lower, respectively). Countries
that may have included persons between the ages of 5–19 and
20–44 vaccinated with the pandemic vaccine in their sampled
population had higher cumulative incidence than countries
that excluded H1N1pdm vaccinated persons in these same age
groups (19% [95%CI 34–338]higher, 15% [95%CI 31–261]
higher, respectively). When we exclude the two countries,
which suggested that a significant proportion of their study
populations’ seroprevalence may be due to vaccination
(Norway34 and the US39), rather than natural infection, the
overall pooled cumulative incidence is 21% (95%CI 18–25; see
Figure S1) compared with 24% (95%CI 20–27%).
Post-pandemic seroprevalence
Post- pandemic seroprevalence was estimated by pooling
data from nine countries from 10 studies (n sera = 52,479;
Table 1). The overall age-adjusted H1N1pdm seroprevalence
was 32% (95%CI 26–39%; Figure 3C). From age 5, seropre-
valence generally, although not significantly, decreased with
age (Figure 4C) and decreased, not significantly, across all
groups with increasing time interval between sera collection
and peak in influenza virus activity (data not shown). There
were no significant associations between overall seropreva-
lence and any covariate examined. However, for the 0–4 year
old age group, a lower proportion sampled after the epidemic
wave was over (Figure 1b, time period D) were seropositive
compared with sera collected during the decline of the
epidemic (Figure 1b, time period C; OR = 016 95%CI 004–
06). In addition, for the 0–4 year old age group, countries
that may have included persons vaccinated with the
pandemic vaccine in the sampled population had lower
seroprevalence than countries that excluded H1N1pdm-
vaccinated persons (OR = 021 95%CI 006–08).
Discussion
Our study is the first to gather and analyze primary
H1N1pdm serologic data in standardized age groups from
countries/administrative regions across the world. Our
results suggest that approximately 20–27% of the popula-
tions in the included countries were infected with H1N1pdm
virus during the first year of circulation. Incidence was
highest in the 5–19 years age group, where approximately
46% (95% CI 36–56%) were infected, and lowest in the  65
age group, where approximately 11% (95% CI 5–18%) were
infected. Although, as expected, there was some local within-
country variation in infection rates as demonstrated by
individual studies, we found consistency in age-specific
cumulative incidence estimates across countries. This con-
sistency in estimated infection rates by age group between
countries may have been strengthened in part because we
consistently categorized our sera based on timing of collec-
tion in relation to peak H1N1pdm viral activity in each
country. Assuming that the cumulative incidence in the
countries included in our studies is similar to the rest of the
world for which no little data exist and if the global mortality
estimates produced by two research groups1,2 are confirmed
by other studies, this would place the CFR for H1N1pdm at
<002%.
Our results are consistent with our estimates of H1N1pdm
seroprevalence using post-pandemic sera and with other
H1N1pdm seroprevalence studies recently or not yet
published from Iceland, Mexico, Chinese Taipei, India,
Mongolia, Mali,53–56 Laos, Djibouti, and Bolivia (CoPanFlu-
International consortium unpublished data, personal
communication from X. de Lamballerie), with a study from
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Figure 4. Age-specific (A) prevalence of cross-reactive antibodies from
baseline pre-pandemic sera, (B) cumulative incidence of H1N1pdm
infection using pre- and post-pandemic sera and (C) H1N1pdm
seroprevalence from post-pandemic sera. Point estimates indicate pooled
estimate and lines represent relevant 95%CI. Each line represents
unadjusted age-specific results from individual studies. See Tables S1–S3
for studies included in each estimate.
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Greece with pre- and post-pandemic sera that was excluded
from our analyses51 but are slightly higher than the overall
estimated cumulative incidence found in one analysis.17 This
may be because our study includes a number of additional
middle and low countries who conducted serologic studies
because this analysis was published and because we excluded
studies which focused on specialized populations17). Addi-
tionally, the age-specific trends we found in our cumulative
incidence results are consistent with studies which measured
cumulative incidence as a fourfold increase in titers among
paired sera36,42,57 and similar to studies which measured
age-specific secondary attack rates using RT-PCR.58,59
In the analyses of pre-pandemic data, we found increasing
levels of cross-reactive antibodies to H1N1pdm virus with
age, although there were differences in these patterns by
region. For example, older individuals in some Asian
countries had lower levels of cross-reactive antibodies prior
to widespread circulation of the pandemic strain than did
individuals in other regions. However, this was not a
universal finding for all Asian countries and may be a
reflection of the age groups we chose in this meta-analysis
because we collapsed elderly age categories into a single unit
( 65 years of age): some studies observed differences
among the elderly (>65 years old) versus very senior
individuals (i.e., >80 years old, e.g.,25,41,52,60). We note that
regional differences did not persist when only looking at
cumulative incidence from studies in which two sets of sera
from one population were tested in the same laboratory
using the same methodology or in post-pandemic seropre-
valence. Therefore, given the small numbers of studies in
individual regions, these patterns may reflect differences in
laboratory methodology. However, this does not rule out the
possibility that some serologic assays fail to identify anti-
bodies in older individuals, or reflect antibodies among older
individuals in countries without high routine seasonal
influenza vaccination coverage.61 Differences in laboratory
methodology rather than real differences in pre-existing
immunity would also explain the observation that reported
cumulative incidence was not higher in  65 year olds in
Asia where pre-pandemic seroprevalence was found to be
lower.62 We also observed low-level pre-pandemic seropos-
itivity in children (<5%) and adolescents (<10%) in some
countries, which may again be due to assay differences
between laboratories.
There are a few factors that may affect the accuracy of our
estimates. The inherent limitations of combining results
from influenza serologic studies have been widely dis-
cussed12,16,63 and could have an impact on the accuracy of
our estimates. Based on our analyses, we strongly support the
recommendations to standardize influenza seroepidemiolog-
ical studies both in terms of epidemiologic and laboratory
methods. In addition, declining antibody levels over time in
some of the populations studied and the fact that not all
laboratory confirmed H1N1pdm patients seroconvert37,64–67
could have resulted in our results slightly underestimating
the true incidence. We found limited evidence of a decline in
the proportion seropositive over time when looking at the
timing of post-pandemic sera collection in relation to the
peak in H1N1pdm virus activity (data not shown). We found
conflicting results with respect to the impact of vaccination
in our cumulative incidence estimates and post-pandemic
estimates. Because of this and because vaccine coverage in
most of the included countries had reached little of the
population at the time sera were collected (e.g., in the United
States39), and the observed increase was not in age groups
targeted for vaccination, we believe that the H1N1pdm
vaccination has had little impact on our overall cumulative
infection and seroprevalence estimates results. When we
excluded studies that suggest that seroprevalence may be due
to vaccination,34,39 rather than natural infection, the overall
pooled cumulative incidence reduced slightly.
Finally, we were unable to include serological data in our
pooled estimates from all regions of the world – notably
from mainland Africa and Latin America, where to our
knowledge, no H1N1pdm09 seroprevalence data exist.
Despite this, however, we believe that H1N1pdm incidence
may have been similar in all parts of the world because
reported mortality rates and published reports of influenza
activity in Latin America and Africa were similar to those
reported in Europe and North America,54,68,69 and to those
reported in the countries included in our study. The lack of
H1N1pdm morbidity, mortality, and serological data from
Africa,70 however, leaves substantial uncertainty in that
region of the world. Because of the limited number of
countries included in our overall and age-specific cumula-
tive incidence estimates, we were unable to resolve differ-
ences between temperate and tropical counties. While data
from Vietnam and Hong Kong were included and the
incidence estimates – incidence in Vietnam was significantly
lower possibly indicating differences in incidence in rural
areas, and incidence from Hong Kong was consistent with
incidence from the temperate countries included in our
analysis – we are missing serologic data from many other
low- and middle-income tropical and sub-tropical
countries.
Our analysis demonstrates that approximately 24% of the
populations of countries for which there are data were
infected during the first wave of the pandemic, with
incidence reaching 50% in school-age children. This meta-
analysis offers a unique insight into the global impact of the
2009 influenza pandemic in its first year and highlights the
need for seroepidemiological studies to be standardized and
included in pre-pandemic preparedness plans. Together with
estimates of global mortality,1,2 our data have improved our
understanding of the behavior and impact of the influenza
pandemic of 2009.
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